Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Mar 24, 2022 1:22pm
173 Views
Post# 34542165

RE:RE:RE:RE:RE:RE:RE:KRC insight

RE:RE:RE:RE:RE:RE:RE:KRC insight
A quick mention in the Globe and Mail today, along with Pfizer, Thermo Fisher Scientific and Eli Lilly and Co.... and interesting article quoting Eden Rahim, and Chelsea Stellick.  Good exposure for a micro cap being mentioned in same article as the Giants.  

Looking ahead, Chelsea Stellick, Calgary-based iA Capital Markets senior equity research analyst focused on health care and biotech, expects the testing sector to continue to have applications post-pandemic. While testing control companies like Microbix Biosystems Inc. saw significant demand during COVID-19, the need for testing is expected to continue or pick up for other conditions after being put on hold due to the pandemic, she says.
<< Previous
Bullboard Posts
Next >>